Nova Southeastern University
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Aug 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 27, 2027The maintenance fee for Data adaptive compression and data encryption using kronecker products (US 10,397,622) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
- 1 fee due Mar 12, 2027The maintenance fee for Natural Killer (NK) Cells Expressing an Antigen-Specific Functional T Cell Receptor (TCR) Complex, Methods for Production Thereof, and Methods for Therapeutic Use Thereof (US 11,752,172) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 1 fee due Aug 25, 2027The maintenance fee for Epinephrine nanoparticles encapsulated with chitosan and tripolyphosphate, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine (US 10,568,836) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
- 1 fee due Sep 22, 2027The maintenance fee for Modulating oncolytic vesicular stomatitis virus (VSV) with statins for cancer treatment (US 9,289,456) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,939,557 | Vascular endothelial receptor specific inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 7,875,603 | Specific inhibitors for vascular endothelial growth factor receptors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,682,316 | Methods for fabrication of epinephrine bitartrate nanoparticles and epinephrine bitartrate nanoparticles fabricated thereby In force · From the USPTO record | In force | From the USPTO record | |
| US 8,521,490 | Statistical model for predicting falling in humans In force · From the USPTO record | In force | From the USPTO record | |
| US 10,172,907 | Compositions Comprising Beta-Arrestin 1 and Methods of Use Thereof for Therapeutic Modulation of Aldosterone Levels in Heart Disease In force · High confidence | In force | High confidence | |
| US 9,289,456 | Modulating oncolytic vesicular stomatitis virus (VSV) with statins for cancer treatment In force · From the USPTO record | In force | From the USPTO record | |
| US 9,877,921 | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine In force · From the USPTO record | In force | From the USPTO record | |
| US 10,568,836 | Epinephrine nanoparticles encapsulated with chitosan and tripolyphosphate, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine In force · From the USPTO record | In force | From the USPTO record | |
| US 10,251,849 | Sublingual Compositions Including Epinephrine Nanoparticles In force · Medium confidence | In force | Medium confidence | |
| US 11,246,843 | Method for increasing plasma concentration of epinephrine in a subject having a condition responsive to epinephrine In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 21: 5 patents in force now held by others · 4 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 3 abandoned · 26 no status recorded